Guanylate Cyclase (Guanylyl Cyclase)

An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC
Also Known As:
Guanylyl Cyclase; Deoxyguanylate Cyclase; Inosinate Cyclase; Cyclase, Deoxyguanylate; Cyclase, Guanyl; Cyclase, Guanylate; Cyclase, Guanylyl; Cyclase, Inosinate; Guanyl Cyclase; GTP pyrophosphate-lyase (cyclizing)
Networked: 761 relevant articles (32 outcomes, 74 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Stasch, Johannes-Peter: 24 articles (11/2015 - 02/2003)
2. Brouckaert, Peter: 14 articles (06/2015 - 08/2006)
3. Felipo, Vicente: 11 articles (03/2010 - 02/2002)
4. Bloch, Kenneth D: 10 articles (01/2015 - 06/2004)
5. Buys, Emmanuel S: 10 articles (01/2015 - 01/2009)
6. Grimminger, Friedrich: 8 articles (06/2015 - 01/2006)
7. Frey, Reiner: 7 articles (06/2015 - 12/2008)
8. Wolin, Michael S: 7 articles (08/2014 - 08/2003)
9. Olshevskaya, Elena V: 7 articles (04/2014 - 08/2007)
10. Dizhoor, Alexander M: 7 articles (04/2014 - 08/2007)

Related Diseases

1. Pulmonary Hypertension (Ayerza Syndrome)
2. Anoxia (Hypoxia)
3. Constipation
4. Hypotension (Low Blood Pressure)
5. Vasoplegia
05/01/2012 - "In the last 2 decades, studies have reported promising results from the administration of an NO competitor, methylene blue (MB), which is an inhibitor of the soluble guanylate cyclase (sGC), in the treatment of refractory cases of vasoplegia. "
07/01/2009 - "There is strong evidence that methylene blue (MB), an inhibitor of guanylate cyclase, is an excellent therapeutic option for vasoplegic syndrome (VS) treatment in heart surgery. "
06/01/2003 - "Guanylate cyclase inhibitors could be a novel class of agents for the treatment of norepinephrine-refractory vasoplegia after cardiopulmonary bypass. "
05/01/2012 - "Guanylate cyclase inhibition by methylene blue as an option in the treatment of vasoplegia after a severe burn. "
01/01/2008 - "Thus, some points, to a certain extent philosophical, have motivated this revision: a) To preserve and update the surgeon knowledge regarding CPB, even to keep his/her pedagogical leadership on his/her surgical team; b) To question if elderly and diabetic patients, as a result of their individual characteristics deserve more appropriate protocols similar to those adopted for children; c) One third aspect would be the questioning of the systemic inflammatory reaction caused by the blood exposure to CPB non-endothelized circuit surface, in face of the increasing importance of blood contact with the surgical wound; d) In relation to the treatment of the vasoplegic syndrome, methylene blue continues being the best therapeutical option, even so, many times are not efficient on account of a highly probable existence of a "therapeutical window" based on the guanylate cyclase dynamics of action (saturation and synthesis "de novo") and; finally, e) The reason of the title, highlighting that based on its current patterns, would the CPB be an outcome of empiricism, art, or science? "

Related Drugs and Biologics

1. Methylene Blue (Methylthioninium Chloride)
2. riociguat
3. Nitric Oxide Synthase (NO Synthase)
4. Nitric Oxide (Nitrogen Monoxide)
5. linaclotide
6. enterotoxin receptor (guanylyl cyclase C)
7. NG-Nitroarginine Methyl Ester (L-NAME)
8. 5'-Guanylic Acid (GMP)
9. 3- (4- Amino- 5- cyclopropylpyrimidine- 2- yl)- 1- (2- fluorobenzyl)- 1H- pyrazolo(3,4- b)pyridine
10. Cyclic GMP

Related Therapies and Procedures

1. Endarterectomy (Thromboendarterectomy)
2. Cardiopulmonary Resuscitation (CPR)
3. Resuscitation
4. Artificial Respiration (Mechanical Ventilation)
5. Drug Therapy (Chemotherapy)